Company overview

Pioneering from the Start

A history of firsts in interventional cardiology

For more than 25 years, the Biosensors International Group (“Biosensors”) has been designing, manufacturing and marketing innovative medical devices used during heart surgery and intensive care treatment.

Continually striving to be at the forefront of product innovation, with a focus on improving patient outcomes today, we are driving the development of tomorrow’s next generation medical technology.

In the year 2000 we entered the interventional cardiology market and immediately became the first cardiology company to develop and patent their own proprietary limus agent, Biolimus A9™ (BA9™), a highly lipophilic1 anti-restenotic drug designed for cardiovascular stent technologies.

We were also the first stent company to develop and launch a biodegradable polymer stent with only the abluminal side coated with polymer and drug to reduce systemic exposure2.

Over the last two-decades Biosensors has become one of the largest manufacturers and suppliers of cardiovascular stents globally.

Our interventional cardiology products are designed to optimize patient outcomes.

Environmental responsibility

Carbon Footprint Reduction - Sustainable Strategy

Biosensors International strives to reduce its waste through the implementation of lean manufacturing and continuous improvement initiatives, such as energy saving and recycling processes.

Biosensors International has adopted a systematic approach with the implementation of an environmental management system that aims to contribute to environmental sustainability. As a result, three sites are now ISO 14001:2015 certified: the manufacturing site located in Singapore (certified in August 2018), the European warehouse in the Netherlands and the European headquarter offices in Switzerland (both certified in March 2019). Such environmental management system supports Biosensors International's commitment to contribute to protect the environment and respond to changing environmental conditions in balance with socio-economic needs.

We are committed to:

  • Build awareness in our company as well as other persons working under our company’s control in relation to our Environmental Management System and environmental performance, in order to enhance knowledge and promote behavior to achieve continual improvement
  • Identify and having access to compliance obligations and understand how they apply to our company to ensure fulfilment of our compliance obligations
  • Generate appropriate operational controls in order to protect the environment, including prevention of pollution: promoting the use of sustainable resources, striving for recycling, and maximizing the use of primary sources of energy
  • Towards this end, our key objectives include:
    - Continuously improving the efficiency and sustainability of our business activities and products using a life cycle perspective, resulting in the lowering of greenhouse gas emissions and water use wherever feasible
    - Minimizing the generation of hazardous and non-hazardous waste and recycling wastes wherever feasible
    - Reuse, recycle, composting materials and conserve energy wherever feasible.

Our key 2024 objectives are:

In Singapore:

  • Achieve overall objectives hit rate by more than 85%
  • Initiate programs to support BIG decarbonization roadmap, minimum one program/initiative
  • Eliminate use of papers through implementation of electronic platform for QEMS processes
  • Reduce colour printing by another 2%
  • Reduce drug waste by decreasing its retention at incoming
  • Complete building energy audit
  • Implement eDHR for minimum one production line
  • Replace all inkjet printers in order to reduce cartridge wastes
  • Achieve REACH compliance for all new product projects

 In Europe:

  • Sales & MArketing:
    - Not exceed CO2 emissions from EMEA business travels versus 2023 by publishing some rules
    - Maximise digital sponsorship activities: Reduce by 10% printed materials used for meetings
  • Supply chain:
    - Reduce scrapping by 20% compared to max. expected in 2024
    - Reduce by 20% the product stock expiring between January and August 2025
    - Reduce outbound shipments in EMEA direct markets by 20% compared to 2023
  • Clinical activities:
    - Use the tool to measure the carbon footprint of completed trials and identify which elements of trials are carbon-heavy
    - Decrease the impact of clinical trials activities by updating procedures to mandate the following
  • The Investigator meetings, monitoring activities and CEC meetings conducted remotely
  • CRO request of proposal will include the use of electronic signature systems
  • Electronic Investigator Site File will be recommended to all sites participating in “in-house” studies
  • European warehouse:
    - 5% Decrease the normal heating (gas) compared to 2023
    - Work on green heat strategy by 2035 to switch to another energy than gas to heat the building
  • BESA Offices:
    - Commuting policy to be developed for a Go live in 2025 if expected achievement of 15% reduction of CO2 emission can be reached from this policy
    - Implement a common objective with « Ecole de Transition » located in the same building on an EMS topic

Biosensors International UK Decarbonisation plan 2024

Biosensors Vision

We Touch Patients Lives with Pioneering Medical Technologies

Biosensors manufactures and markets innovative medical devices for interventional cardiology.

Our aim is to improve patients’ lives through pioneering medical technology that pushes the boundaries of innovation.

Through our high quality medical devices we impact the lives we touch and we are committed to continued investment in the development of pioneering medical technology, robust clinical data and engineering new medical devices that will further benefit your patients.

This will create the greatest possible patient outcomes and provide value to our stakeholders including customers, employees, communities and shareholders.

Global Presence

The Biosensors International Group has operations worldwide and is headquartered in Singapore. The European headquarters are located in Morges (Switzerland). With the combination of a direct sales network and distributors across the world, Biosensors is dedicated to serving the needs of the healthcare community and is committed to, the support of bona fide medical education, advancing the progress of medical science and improving patient care, through training courses, scientific summits and symposia and related events on a regular basis, both in international forums and at national level. Biosensors also participate in some of the major cardiology congresses throughout the world - doing so in a way that complies with all ethical and legal requirements.

11181-000-EN - Rev.04 - 11940-000-EN - Rev.01

1.    Data on file Biosensors International Group Ltd – Report RD – 200020 - Validation / Verification of ElogPoct Determination Method and Measurement of ElogPoct for Zotarolimus
2.    Ostojic and al - The pharmacokinetics of Biolimus A9 after elution from the BioMatrix II stent in patients with coronary artery disease: The Stealth PK Study; Ostojic et al., Eur J Clin Pharmacol (2011) 67:389–398

CAUTION: Please note that the following pages are exclusively reserved for Health Care Professionals in countries with applicable health authority product registrations. To the extent this site contains information intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions. Please contact your Biosensors International representative for availability or the products and registration status.

The law restricts these devices to sale by or on the order of a physician. Prior to use, it is important to read the "Instructions for Use" supplied with these devices for indications, contraindications, suggested procedures, warnings, and precautions.

Biosensors’ interventional cardiology products, including BioMatrix NeoFlex™, BioMatrix™ Alpha, BioFreedom™, BioFreedom™ Ultra, BMX-J®, RISE™ NC, are not available for sale in the United States and certain other countries. ALLEGRA™ is a product of NVT AG. Blue Sail Medical Co., Ltd is the parent company of NVT AG and Biosensors International Group, Ltd. and its affliates are collaborating for the commercialization of the ALLEGRA™ device.

BioMatrix NeoFlex, BioMatrix Alpha, BioFreedom, BioFreedom Ultra, BMX-J, Juno, S-Stent, Rise NC and Quadrature Link are trademarks or registered trademarks of Biosensors International Group, Ltd. ALLEGRA is a trademark or registered trademark of NVT AG. ALLEGRA™ is CE Mark approved (CE 0124). All other cited trademarks are the property of their respective owners.